 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1213141516171819202122...235236» |
- ||| PF-07934040 / Pfizer
Enrollment open, IO biomarker, Metastases: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov) - Jul 4, 2024
P1, N=330, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting
- | Journal: A fresh perspective on advances in pancreatic cancer treatment over the past two decades (Pubmed Central) - Jul 3, 2024
In the past two decades, significant advances have been made in the treatment of pancreatic cancer.Numerous first-line treatments, such as gemcitabine combined with erlotinib, gemcitabine combined with albumin-bound paclitaxel, FOLFIRINOX, and NALIRIFOX, have emerged;surgery-centered treatment has gradually become the mains clinical strategy.However, behind these achievements, the new drugs developed with substantial funding have not extended the median survival time of patients with advanced pancreatic cancer to more than one year; the 5-year survival rate for postoperative patients remains below 30%. While harboring hope and being proactive, researchers must also soberly reflect and continually reassess our direction, in anticipation of bringing tangible clinical benefits to pancreatic cancer patients at an early date.
- | methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Direct Visualization of a Cesarean Scar Ectopic Pregnancy After Medical Management. (Pubmed Central) - Jul 3, 2024
Following the diagnosis, she was treated by multi-dose systemic methotrexate-leucovorin and with ultrasound-guided intra-gestational sac injection of potassium chloride...CONCLUSIONS Direct visualization of the intra-abdominal cavity and intra-uterine cavity showed that combined medical management with systemic methotrexate and local potassium chloride injection is an effective treatment modality for live cesarean scar ectopic pregnancies, with minimal anatomical harm. Hysteroscopic resection offers a safe and effective approach for removal of persistence of residual tissue.
- | erlotinib / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P1/2 trial, Metastases: PANGEA: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (clinicaltrials.gov) - Jul 3, 2024
P1/2, N=104, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jul 2, 2024
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Hysteroscopic resection offers a safe and effective approach for removal of persistence of residual tissue. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- | Journal: The Debut Signal of Bone Metastasis and Stealthy Gastric Cancer Unmasked in a Young Male: A Case Report. (Pubmed Central) - Jul 1, 2024
The patient was planned to start on palliative chemotherapy (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel {FLOT} regimen) with palliative radiotherapy of 20 Gy in five fractions to bony metastasis. The patient denied treatment and was discharged against medical advice.
- || Avastin (bevacizumab) / Roche
Clinical, Retrospective data, Journal: PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma. (Pubmed Central) - Jun 28, 2024
Both atezolizumab (a PD-L1 inhibitor) plus bevacizumab (A+B) and sintilimab (a PD-1 inhibitor) plus bevacizumab (S+B) are recommended as the first-line regimen for advanced hepatocellular carcinoma (HCC) in China...No significant differences were observed in grade 3-4 TRAEs between groups. Either PD-L1 or PD-1 inhibitor plus bevacizumab combined with TACE-HAIC have similarly excellent therapeutic efficacy with manageable adverse events, representing promising treatment options for uHCC.
- || Onivyde (nanoliposomal irinotecan) / Ipsen
Enrollment closed, Enrollment change: SIRACUSA: A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (clinicaltrials.gov) - Jun 28, 2024
P1, N=177, Active, not recruiting, Sponsor: Ipsen
Either PD-L1 or PD-1 inhibitor plus bevacizumab combined with TACE-HAIC have similarly excellent therapeutic efficacy with manageable adverse events, representing promising treatment options for uHCC. N=122 --> 177 | Recruiting --> Active, not recruiting
- || P1/2 data, Journal, Metastases: Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. (Pubmed Central) - Jun 27, 2024
P1/2
Mitazalimab with mFOLFIRINOX demonstrated manageable safety and encouraging activity, warranting continued development in a phase 3, randomised, controlled trial. The results from OPTIMIZE-1 pave the way for further exploration and confirmation of a novel immunotherapy treatment regimen for metastatic pancreatic ductal adenocarcinoma, which is a complex and aggressive cancer with very low survival rates and restricted treatment options.
- | Preclinical, Journal: Relationships Among Serological Indicators and In Vitro High-Throughput Drug Sensitivity Screening Results in Patients with Hepatocellular Carcinoma. (Pubmed Central) - Jun 27, 2024
NLR, SII, and SIRI were correlated with FOLFOX4, and the higher the values of NLR, SII, and SIRI, the higher the in vitro inhibition of FOLFOX. Also, NLR was correlated with XP, and the higher the value of NLR, the higher the in vitro inhibition of XP.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Prognostic value of tumor regression grade (TRG) after oncological gastrectomy for gastric cancer. (Pubmed Central) - Jun 27, 2024
Also, NLR was correlated with XP, and the higher the value of NLR, the higher the in vitro inhibition of XP. TRG 1-2 was associated with less advanced ypT and ypN stage and better DFS compared to TRG 3-5 patients, without a significant impact on OS.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Retrospective data, Journal: Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies. (Pubmed Central) - Jun 27, 2024
This approach should consider not only the traditional metrics such as tumor stage and histological grading but also incorporate a broader spectrum of biomarkers. Future studies should aim to validate these findings and explore the integration of these biomarkers into routine clinical practice, enhancing the precision of prognostic assessments and ultimately guiding more personalized treatment strategies for CRC patients.
- | leucovorin calcium / Generic mfg.
New P1 trial: CFT-SPG56: Calcium Folinate Treatment of Spastic Paraplegia 56 (clinicaltrials.gov) - Jun 27, 2024
P1, N=10, Recruiting, Sponsor: Shanghai 6th People's Hospital
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Retrospective data, Journal: Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. (Pubmed Central) - Jun 26, 2024
In patients ?70 years with stage III CC fit enough to be enrolled in clinical trials, oxaliplatin-based adjuvant chemotherapy was well tolerated and led to similar TTR compared with younger patients, suggesting similar efficacy. TTR may be a more appropriate end point for efficacy in this patient population.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Retrospective data, Journal, Metastases: Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. (Pubmed Central) - Jun 26, 2024
This study represents the largest real-world population of mPC patients treated with AG as a second or later line of therapy. It supports the feasibility of this regimen following first-line FOLFIRINOX, particularly in patients with specific clinical and laboratory characteristics who derived prolonged benefit from first-line therapy.
- | gemcitabine / Generic mfg.
Preclinical, Journal: miRNA signatures underlie chemoresistance in the gemcitabine-resistant pancreatic ductal adenocarcinoma cell line MIA PaCa-2 GR. (Pubmed Central) - Jun 26, 2024
These findings suggest potential targets for improving prognosis and tailoring treatment strategies in PDAC patients, particularly those showing resistance to gemcitabine. Future research should focus on validating these miRNAs as biomarkers for resistance and exploring their therapeutic potential in overcoming chemoresistance.
- | New P2 trial: FUDOSE: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme (clinicaltrials.gov) - Jun 26, 2024
P2, N=400, Not yet recruiting, Sponsor: UNICANCER
- ||||| bemarituzumab (AMG 552) / Amgen
Enrollment closed, Metastases: FORTITUDE-101: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov) - Jun 25, 2024
P3, N=516, Active, not recruiting, Sponsor: Amgen
Future research should focus on validating these miRNAs as biomarkers for resistance and exploring their therapeutic potential in overcoming chemoresistance. Recruiting --> Active, not recruiting
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Combination therapy, Metastases: Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 25, 2024
P2, N=87, Recruiting, Sponsor: Fudan University
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Journal, Metastases: Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma. (Pubmed Central) - Jun 25, 2024
Recruiting --> Active, not recruiting Preoperative DCF for resectable EGJ-AC was well tolerated and has promising efficacy.
- nisevokitug (NIS793) / Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: FOLFIRINOX + NIS793 in Pancreatic Cancer (clinicaltrials.gov) - Jun 25, 2024
P1, N=4, Terminated, Sponsor: Colin D. Weekes, M.D., PhD
Preoperative DCF for resectable EGJ-AC was well tolerated and has promising efficacy. N=50 --> 4 | Trial completion date: May 2025 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jul 2023; NIS793 is no longer being developed
- | Trial completion date, Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Jun 23, 2024
P2, N=40, Active, not recruiting, Sponsor: Chinese University of Hong Kong
N=50 --> 4 | Trial completion date: May 2025 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jul 2023; NIS793 is no longer being developed Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Trial completion date, Trial primary completion date, Metastases: FOLFOXIRI With or Without Intensification for Rectal Cancer (clinicaltrials.gov) - Jun 23, 2024
P2, N=72, Recruiting, Sponsor: CCTU
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Dec 2025
- | 5-fluorouracil / Generic mfg.
Journal: Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. (Pubmed Central) - Jun 22, 2024
Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Dec 2025 This study presents a transcriptome-based tool that was developed using preclinical models and machine learning to accurately predict sensitivity to mFFX and gemcitabine.
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Jun 21, 2024
P1, N=282, Recruiting, Sponsor: Amgen
This study presents a transcriptome-based tool that was developed using preclinical models and machine learning to accurately predict sensitivity to mFFX and gemcitabine. Trial completion date: May 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Nov 2025
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: NALIRIFOX as Induction Therapy in LAPC (clinicaltrials.gov) - Jun 21, 2024
P2, N=20, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. (Pubmed Central) - Jun 20, 2024
P2
K17 and ctDNA are promising biomarkers that require additional validation in future prospective studies. ClinicalTrials.gov Identifier: NCT02047474.
- || 5-fluorouracil / Generic mfg.
Review, Journal, Metastases: Intra-arterial Chemotherapy in Patients With Metastatic or Locally Aggressive Pancreatic Adenocarcinoma: A Scoping Review. (Pubmed Central) - Jun 20, 2024
ClinicalTrials.gov Identifier: NCT02047474. When IAC
- || Enrollment closed: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Jun 20, 2024
P1, N=422, Active, not recruiting, Sponsor: Hoffmann-La Roche
When IAC Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Observational data, Journal, Combination therapy, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Prospective, Observational Study of Aflibercept Use in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer: A Real-World Effectiveness Study. (Pubmed Central) - Jun 19, 2024
Recruiting --> Active, not recruiting The benefits/risks of Aflibercept plus FOLFIRI administered per the Polish reimbursement criteria in second-line treatment of mCRC after failure of a prior oxaliplatin-based regimen is confirmed.
- | 5-fluorouracil / Generic mfg.
Reimbursement, US reimbursement, Journal: The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. (Pubmed Central) - Jun 19, 2024
Background/Objectives: The survival rate of patients with pancreatic cancer (PC) has improved gradually since the introduction of FOLFIRINOX (FFX) and gemcitabine + albumin-bound paclitaxel (GnP) regimens...As initial palliative chemotherapy, 3823 patients (25.90%) received gemcitabine alone; 2779 (18.83%) received gemcitabine + erlotinib; 1948 (13.20%) received FFX; and 1767 (11.97%) received GnP...Radiation therapy (aHR, 0.667; 95% CI, 0.612-0.728) and second-line chemotherapy (aHR, 0.639; 95% CI, 0.597-0.684) were significantly associated with improved survival. Our study found that first-line chemotherapy with FFX was associated with significantly longer survival than the other regimens, although caution is needed in interpreting the results.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer. (Pubmed Central) - Jun 19, 2024
The inhibition of ERK by U0126 led to a significant reduction in IL-8 secretion, and the combination therapy of U0126 with FOLFOX optimizes the response of corresponding cancer cell lines. Therefore, we hypothesize that the combination therapy of FOLFOX and U0126 may have great potential to improve drug efficacy on this subgroup of CRCs, showing decreased MLH1 and SPTAN1 accompanied with high serum IL-8 in affected patients.
- | Preclinical, Journal, IO biomarker: Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320. (Pubmed Central) - Jun 19, 2024
The measurement of cytotoxic activity using the Chou-Talalay combination index approach revealed that PD-H synergistically enhanced the cytotoxic activity of oxaliplatin (OX), 5-fluorouracil (5-FU) and SN-38...Moreover, the drug treatment did not increase the mutation rate of the miR-TS inserted into the PD-H genome. The results demonstrate that the combination of FOLFOXIRI drugs and PD-H may be a promising approach to enhance the therapeutic effect of FOLFOXIRI therapy in CRC.
- | Retrospective data, Journal, Real-world evidence, Claims database, Real-world: Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Study. (Pubmed Central) - Jun 18, 2024
This study revealed the treatment reality of pancreatic cancer in the real-world Japanese setting. Treatment duration and time to death tended to increase over time and did not differ numerically between FOLFIRINOX and GEM + nab-PTX.
- 5-fluorouracil / Generic mfg.
Observational data, Journal: Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. (Pubmed Central) - Jun 18, 2024
Although pCR does not reflect cure, it is associated with improved OS, with a doubled 5-year OS of 63% compared with 30% in patients without pCR. Factors associated with pCR related to preoperative chemo(radio)therapy regimens and anatomical and biological disease response features may have implications for treatment strategies that require validation in prospective studies because they may not universally apply to all patients with pancreatic adenocarcinoma.
- | 5-fluorouracil / Generic mfg.
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer. (Pubmed Central) - Jun 18, 2024
Downregulation of CD3/CD4 expression in the tumor and stroma is related to pCR. However, the molecular mechanisms underlying PD-1 blockade-enhanced targeted chemotherapy require further investigation.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Journal: Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer. (Pubmed Central) - Jun 18, 2024
CAF subtypes have an additive effect over tumor-intrinsic subtypes in predicting survival with or without neoadjuvant FOLFIRINOX in PDAC. Molecular subtyping of both tumor and CAF compartments of PDAC may be important steps in selecting first-line systemic therapy.
- | Braftovi (encorafenib) / Pfizer
Trial completion date, Metastases: NAUTICALCRC: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (clinicaltrials.gov) - Jun 17, 2024
P2, N=103, Active, not recruiting, Sponsor: Pierre Fabre Medicament
Molecular subtyping of both tumor and CAF compartments of PDAC may be important steps in selecting first-line systemic therapy. Trial completion date: Apr 2024 --> Jan 2025
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Surgery: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. (Pubmed Central) - Jun 16, 2024
Trial completion date: Apr 2024 --> Jan 2025 This study demonstrates that in patients who undergo surgical resection after receipt of long-duration neoadjuvant FOLFIRINOX therapy alone, survival outcomes are similar regardless of pretreatment resectability status and that favorable surgical outcomes can be attained.
- | Avastin (bevacizumab) / Roche
Biomarker, Journal, Metastases: Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial. (Pubmed Central) - Jun 14, 2024
This study demonstrates that in patients who undergo surgical resection after receipt of long-duration neoadjuvant FOLFIRINOX therapy alone, survival outcomes are similar regardless of pretreatment resectability status and that favorable surgical outcomes can be attained. We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress.
- ||| sirexatamab (DKN-01) / Leap Therap
Enrollment change, Metastases: DeFianCe: Phase 2 Study of DKN-01 in Colorectal Cancer (clinicaltrials.gov) - Jun 13, 2024
P2, N=200, Recruiting, Sponsor: Leap Therapeutics, Inc.
We identified a CAF marker combination that indicates treatment resistance to FOLFOX plus bevacizumab in patients with mCRC within 100 days prior to radiologic progress. N=150 --> 200
- |||| oxaliplatin / Generic mfg.
New P2 trial: The METIMMOX study - treatment with FLOX chemotherapy with the addition of immune therapy for patients with spread of cancer from the large bowel. (EUDRACT) - Jun 13, 2024
P2, N=100, Completed, Sponsor: Akershus University Hospital
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab. (Pubmed Central) - Jun 13, 2024
The patient initially responded well, but his disease progressed 2 months later. Further research is needed to improve management strategies for BRAF V600E-mutated colorectal cancer with CNS metastases.
- ||||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead
Enrollment closed, Trial completion date, Trial primary completion date: STAR-221: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (clinicaltrials.gov) - Jun 11, 2024
P3, N=1040, Active, not recruiting, Sponsor: Arcus Biosciences, Inc.
Further research is needed to improve management strategies for BRAF V600E-mutated colorectal cancer with CNS metastases. Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Sep 2026 --> May 2026
- | irinotecan / Generic mfg.
Enrollment open, Phase classification, Metastases: Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jun 11, 2024
P=N/A, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Sep 2026 --> May 2026 Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A
- | bemarituzumab (AMG 552) / Amgen
Journal, Metastases: Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. (Pubmed Central) - Jun 11, 2024
P2
Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A In East Asian patients with FGFR2b-positive advanced/metastatic G/GEJC enrolled in the global FIGHT study, bemarituzumab-mFOLFOX6 showed clinically meaningful outcomes over placebo-mFOLFOX6.
- || nisevokitug (NIS793) / Novartis
Trial primary completion date: daNIS-3: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (clinicaltrials.gov) - Jun 11, 2024
P2, N=204, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
In East Asian patients with FGFR2b-positive advanced/metastatic G/GEJC enrolled in the global FIGHT study, bemarituzumab-mFOLFOX6 showed clinically meaningful outcomes over placebo-mFOLFOX6. Trial primary completion date: May 2024 --> Sep 2024
- | New P2 trial, Metastases: ABLATE: A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment (clinicaltrials.gov) - Jun 11, 2024
P2, N=47, Not yet recruiting, Sponsor: University Health Network, Toronto
- Trial termination: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Jun 11, 2024
P1/2, N=3, Terminated, Sponsor: ImmunityBio, Inc.
Trial primary completion date: May 2024 --> Sep 2024 Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- || olaptesed pegol (NOX-A12) / TME Pharma
Trial completion date, Trial primary completion date, Metastases: OPTIMUS: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (clinicaltrials.gov) - Jun 11, 2024
P2, N=60, Not yet recruiting, Sponsor: TME Pharma AG
Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Oct 2027